Brainstorm Cell Therapeutics Inc.
BCLI
$1.00
$0.011.01%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -32.79% | 25.73% | 18.13% | 22.23% | -14.25% |
| Total Depreciation and Amortization | -9.80% | -28.85% | -9.43% | -18.64% | -20.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 357.46% | -81.45% | 341.10% | 172.69% | 159.28% |
| Change in Net Operating Assets | 153.17% | 37.28% | -26.40% | 284.10% | -292.17% |
| Cash from Operations | 74.44% | 19.07% | 29.39% | 66.60% | -108.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -68.89% | -- | -- | -- |
| Total Debt Repaid | 88.63% | -- | -- | -- | -- |
| Issuance of Common Stock | -69.46% | 41.61% | -- | -- | -23.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -66.75% | -59.49% | -26.28% | -- | -38.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.37% | -104.81% | 81.82% | 76.08% | -129.81% |